WISE S.p.A. (wiseneuro.com), an Italy-based developer of ultra-thin stretchable implantable neuroelectrodes, has raised €30 million in Series D funding. The round welcomed ENEA Tech and Biomedical as a strategic investor. WISE's proprietary Supersonic Technology produces soft, flexible electrodes that conform better to neural tissue than rigid conventional designs for neuromonitoring and neuromodulation applications. The capital will advance the Heron lead through regulatory certification and first-in-human studies while scaling commercialization of the WISE Cortical Strip.
Regulatory Moat Strengthens European Position
The timing aligns with Europe's Medical Device Regulation transition. WISE became the first cortical strip for intraoperative neuromonitoring to achieve CE mark under MDR in July 2025. NeuroOne Medical Technologies raised approximately $8.2 million in April 2025. WISE's approach using stretchable electronics on elastomeric foils addresses conformability gaps that limit rigid electrode performance in brain surface applications.
Rigid Electrodes Limit Surgical Precision
Traditional cortical strips rely on rigid metal contacts that fail to conform closely to brain tissue, resulting in higher impedance and weaker signal quality during tumor and epilepsy procedures. Hospitals performing intraoperative neuromonitoring face trade-offs between procedural safety and monitoring accuracy. Existing solutions from Ad-Tech Medical and DIXI Medical remain anchored in decades-old rigid designs.
Stretchable Platform Bridges Monitoring and Stimulation
WISE Cortical Strip is commercially available across Europe, the US, and Australia with MDR, FDA, and TGA clearances. Its Heron lead combines the directional precision of surgical paddle leads with percutaneous minimally invasive delivery for spinal cord stimulation in chronic pain. This eliminates the need for open surgery while maintaining targeted stimulation coverage.
As CEO Luca Ravagnan noted:
"With the Heron lead, we are targeting a multi-billion-euro market with a product that addresses a long-lasting unmet clinical need."
Strategic Capital Validates Platform Potential
ENEA Tech and Biomedical, a foundation supervised by Italian ministries, joined alongside existing backers including the European Investment Bank. The oversubscribed round signals institutional conviction in WISE's materials science approach. Chair Laura Iris Ferro, founder of Gentium acquired for approximately $1 billion, adds governance depth from successful European biotech exits.
Neuromodulation Market Expands Steadily
The neuromodulation market stands at $6.67–6.81 billion in 2025 and is projected to reach $10.68–10.93 billion by 2030. Spinal cord stimulation accounts for roughly 45 percent of revenue. WISE competes with established players Medtronic, Abbott, and Boston Scientific in stimulation alongside monitoring incumbents. Its platform spans monitoring, stimulation, and future brain-computer interface uses from a single stretchable electrode technology.
Leadership Upgrade Signals Scale Ambitions
New Chair Laura Iris Ferro brings direct experience scaling a biotech company to a major exit. Combined with board additions and clinical advisors such as Dr. Tim Deer, the team is positioned to navigate global commercialization and clinical validation for the Heron pipeline.